Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (71-80 of 162) with videos related to

Pageof 17
Sort By:
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
Leukemia Research|February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2015
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation studyJohn F DiPersio, Harry P Erba, Richard A Larson, et al.
Haematologica|July 11, 2015
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOGRoland B Walter, Megan Othus, Bob Löwenberg, et al.
Cancer|February 22, 2017
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trialsXiaoyu Qu, Megan Othus, Jerry Davison, et al.
Blood Advances|June 30, 2019
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemiaHarry P Erba, Pamela S Becker, Paul J Shami, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
Blood Advances|April 25, 2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)Jeffrey E Lancet, Anna B Moseley, Steven E Coutre, et al.
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Pageof 17

Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
Leukemia Research|February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2015
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation studyJohn F DiPersio, Harry P Erba, Richard A Larson, et al.
Haematologica|July 11, 2015
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOGRoland B Walter, Megan Othus, Bob Löwenberg, et al.
Cancer|February 22, 2017
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trialsXiaoyu Qu, Megan Othus, Jerry Davison, et al.
Blood Advances|June 30, 2019
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemiaHarry P Erba, Pamela S Becker, Paul J Shami, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
Blood Advances|April 25, 2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)Jeffrey E Lancet, Anna B Moseley, Steven E Coutre, et al.
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Pageof 17